Chewy (CHWY) Q1 2026 Earnings Transcript

Chewy reported Q1 net sales of $3.36 billion, up 7.7% year over year, with adjusted EBITDA margin expanding 130 bps to 7.5% and free cash flow rising more than 45% to $71 million. Management trimmed the outlook for customer adds and NSPAC growth due to a more challenged consumer backdrop, but maintained full-year 2026 revenue guidance of $13.40 billion to $13.55 billion and EBITDA margin guidance of 6.6% to 6.8%. The quarter also featured $200 million of buybacks, a new $600 million term loan, and continued expansion in Vet Care and AI initiatives.

Analysis

Chewy is morphing from a pure e-commerce compounder into a cash-generative vertical platform, and that matters because the market tends to underwrite only the core retail multiple while underappreciating the embedded health, ads, and fulfillment optionality. The most important second-order effect is not the mid-year guide trim itself; it is that management is explicitly preserving margin expansion while admitting near-term demand softness, which implies the business is increasingly able to self-fund growth even in a weaker tape. That reduces dilution risk, improves buyback durability, and makes the equity less sensitive to small top-line misses than it was two years ago.

The real signal in the call is that customer acquisition is becoming more efficient at the same time the company is broadening its offline footprint. Veterinary clinics are not just a revenue add-on; they are a low-churn acquisition funnel that appears to shorten payback versus paid digital channels and lift first-year spend materially. If that holds, Chewy’s health segment could act as a flywheel that partially offsets softer discretionary attach rates in the core business, with the clinic layer also raising switching costs and improving cohort quality over the next 12-24 months.

The near-term risk is that the market extrapolates the guidance reset into a structural deceleration, when the more likely issue is cyclical pressure on premium mix and basket depth. That creates a window where the stock can de-rate even as EBITDA and FCF still expand, especially if investors focus on the slower customer-add cadence rather than the still-healthy reactivation and Autoship base. The consumer backdrop is the key catalyst to monitor over the next two quarters: if attach rates stabilize and gross margin normalizes after the comparison reset, the setup for a second-half re-acceleration is credible.

The contrarian view is that the stock may already be pricing in too much caution relative to the earnings power inflecting beneath the surface. AI savings, sponsored ads, and clinic economics are all incremental margin levers that can compound faster than the revenue line, which means the upside is likely to come from multiple expansion on margin durability rather than a dramatic growth re-rate. The biggest mistake would be treating CHWY as a low-growth consumer name instead of a high-quality cash compounder with multiple embedded operating options.

Key Decisions for Investors

• Long CHWY on weakness over the next 1-3 weeks; use any post-guidance selloff to build a position with a 6-12 month horizon. Risk/reward is attractive if the market is overreacting to NSPAC softness while FCF and margin expansion remain intact.
• Pair trade: long CHWY / short AMZN for 3-6 months. Thesis: Chewy has more direct operating leverage from health, ads, and clinics, while AMZN remains a broader consumer/macro exposure and a source of incremental competitive noise.
• Buy CHWY Jan-2027 call spreads if implied vol compresses after the print. The setup is for multiple expansion once the market gains confidence that Q2 is the trough on margin cadence and that 2027 AI savings are real.
• For a lower-risk expression, sell cash-secured puts on CHWY 10-15% below spot with 2-4 month tenor. This monetizes elevated uncertainty around consumer softness while targeting entry into a structurally improving cash generator.
• Watch AMZN same-day grocery announcements and broader pet retail promo intensity; if either accelerates meaningfully, reduce CHWY exposure because the thesis is more about mix pressure than outright share loss.